Influence of low tumor content on tumor mutational burden estimation by whole‐exome sequencing and targeted panel sequencing

Influence of low tumor content on tumor mutational burden estimation by whole‐exome sequencing and targeted panel sequencing

Abstract Background Tumor mutational burden (TMB) is a promising biomarker for stratifying patient subpopulation who would benefit from immune checkpoint blockade (ICB) therapies. Although great efforts have been made for standardizing TMB measurement, mutation calling and TMB quantification can be...

Full description

Bibliographic Details
Main Authors: Wenxin Zhang, Ruixia Wang, Huan Fang, Xiangyuan Ma, Dan Li, Tao Liu, Zhenxi Chen, Ke Wang, Shiguang Hao, Zicheng Yu, Zhili Chang, Chenglong Na, Yin Wang, Jian Bai, Yanyan Zhang, Fang Chen, Miao Li, Chao Chen, Liangshen Wei, Jinghua Li, Xiaoyan Chang, Shoufang Qu, Ling Yang, Jie Huang
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Clinical and Translational Medicine
Subjects:
biomarker
targeted panel sequencing
tumor mutational burden
whole‐exome sequencing
Online Access:https://doi.org/10.1002/ctm2.415

Internet

https://doi.org/10.1002/ctm2.415

Similar Items